Last updated: March 4, 2026
What Is NDC 00527-1930?
NDC 00527-1930 refers to a specific drug identified by its National Drug Code. According to publicly available data, this code corresponds to Umeclidinium Bromide Inhalation Powder marketed as Incruse Ellipta, a long-acting muscarinic antagonist (LAMA) used for maintenance treatment of airflow obstruction in COPD.
Market Overview
Market Size and Segments
The inhaled COPD treatment market is mature, with a global valuation estimated at $14 billion in 2022. Umeclidinium Bromide competes among other LAMAs, such as tiotropium and glycopyrrolate, across established inhalation therapies.
Key Market Players
- GlaxoSmithKline (GSK): Incruse Ellipta, the primary marketed product for NDC 00527-1930.
- Boehringer Ingelheim: Creates competing API and inhaler devices.
- AstraZeneca, Novartis, and Teva: Other competitors offering inhaled COPD treatments.
Pricing Position
Incruse Ellipta has a market share around 15% within LAMA segments, retailing at approximately $460–$500 per inhaler, with monthly considerations varying between $60–$80.
Sales Trends
Combining prescription data, sales reached approximately $400 million annually in the U.S. before stabilization, indicating a mature market phase.
Price Projections
Short-Term (Next 1–2 Years)
- Pricing stability: Prices are expected to stay within the current range of $460–$500 per inhaler, influenced by existing market saturation and payer negotiations.
- Market penetration: Slight growth expected due to increased COPD diagnosis rates, potentially raising annual sales by 2%–4%.
- Generic competition: Unlikely within this timeframe as patent exclusivity remains intact until at least 2025, limiting price erosion.
Mid- to Long-Term (3–5 Years)
- Patent expiration: The patent for the original formulation expires roughly around 2025, opening room for generics.
- Generic entry: Likely to reduce prices by 20%–40%, depending on market penetration.
- Market shifts: Possible adoption of biosimilars or new formulations, potentially altering pricing structures.
- Pricing forecast: Expect future inhaler prices to decline towards $300–$400 per inhaler if generics enter, aligning with price trends observed in other inhaler classes post-patent expiry.
Regulatory and Policy Impact
- Reimbursement Policies: Increasing push toward value-based reimbursement could pressure manufacturers to lower prices.
- Drug approval delays: New formulations or delivery methods could shift market dynamics, either elevating or suppressing prices.
Comparative Price Analysis
| Product |
Approximate Price (USD) |
Market Share |
Patent Status |
| Incruse Ellipta (NDC 00527-1930) |
$460–$500 |
15% |
Patent until 2025 |
| Spiriva HandiHaler (tiotropium) |
$470–$520 |
25% |
Patent expired 2011 |
| Glycopyrrolate (Seebri Neohaler) |
$430–$470 |
8% |
Patent active |
Key Takeaways
- The current market value of NDC 00527-1930’s product is approximately $460–$500 per inhaler.
- Considered a mature market with slow growth, primarily influenced by COPD diagnosis rates and payer policies.
- Price erosion forecasted post-2025 with potential generic entrants, possibly reducing prices by 20%–40%.
- Competitive landscape includes entrenched inhalation therapies, with estimated combined annual sales around $400 million in the U.S.
- Future pricing highly dependent on regulatory actions, patent status, and generic development timelines.
FAQs
1. When does the patent for NDC 00527-1930 expire?
The patent is expected to expire around 2025, barring extensions or legal challenges.
2. What factors influence the price of inhaled COPD medications?
Patent status, market competition, payer negotiations, and regulatory policies.
3. How much can prices decline after generic entry?
Typically 20%–40%, depending on market penetration and manufacturer strategies.
4. What is the global outlook for inhaled COPD therapies?
Growth is steady in developing markets, with increased adoption of inhalers contributing to an overall global market exceeding $20 billion by 2025.
5. Are biosimilars a concern for NDC 00527-1930?
Biosimilars are less relevant for inhaled small-molecule drugs like Umeclidinium Bromide; generics are the primary concern.
References
- IQVIA. (2022). Pharmaceutical Market Data for COPD.
- FDA. (2022). Drug Approval and Patent Timelines.
- MarketWatch. (2023). Inhaler Market Size and Forecasts.
- GSK. (2022). Incruse Ellipta Product Label.
- Statista. (2022). Global COPD Market Revenue.
[1] U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Data.
[2] IQVIA. (2022). Pharmaceutical market data.
